Domvanalimab and Zimberelimab in Advanced Liver Cancers
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about advanced liver and bile duct cancers. The
main question it aims to answer is:
If the combination of Domvanalimab and Zimberelimab are effective in treating advanced
hepatobiliary cancers that have failed prior treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Arcus Biosciences, Inc. Cancer Prevention Research Institute of Texas